Development of a fibromyalgia-specific quality of life instrument: the Fibromyalgia Quality of Life Scale (FM-QoLS).

IF 3.2 3区医学 Q2 RHEUMATOLOGY

Rheumatology International Pub Date : 2025-05-16 DOI:10.1007/s00296-025-05895-3

Ilke Coskun Benlidayi, Ceren Ornek, Aylin Sariyildiz, Yasar Sertdemir

{"title":"Development of a fibromyalgia-specific quality of life instrument: the Fibromyalgia Quality of Life Scale (FM-QoLS).","authors":"Ilke Coskun Benlidayi, Ceren Ornek, Aylin Sariyildiz, Yasar Sertdemir","doi":"10.1007/s00296-025-05895-3","DOIUrl":null,"url":null,"abstract":"<p><p>The study aimed to develop a quality of life (QoL) scale specific to patients with fibromyalgia. The scale development involved four steps: (1) Issue collection, (2) Face validity and selection of the most relevant items, (3) Formation of the preliminary scale and pilot testing, and (4) Psychometric evaluation. For psychometric evaluation, the scale was administered to a sample of fibromyalgia patients. Suitability for exploratory factor analysis (EFA) was assessed using the Kaiser-Meyer-Olkin (KMO) test and Bartlett's Test of Sphericity. Reliability was assessed with Cronbach's alpha, Guttman split-half test, and test-retest correlations. Construct validity was determined via EFA using Principal Axis Factoring. The correlation of the developed scale with established measures of QoL, fibromyalgia impact, fatigue, sleep, and mood was tested to assess convergent validity. Floor and ceiling effects were also examined. The initial item list included 25 issues related to QoL in fibromyalgia. Following the assessments and rating of the initial issue list through cognitive interviews, 10 issues were removed. The remaining questions were administered to 60 patients with fibromyalgia. The final version of the Fibromyalgia Quality of Life Scale (FM-QoLS) contained 14 items and two domains: symptomatology-functionality and psychosocial. Moderate-strong correlations between most items indicated that the scale has a homogeneous structure and measures the same construct. The FM-QoLS showed moderate-strong correlations with pain, anxiety, depression, sleep, fatigue, and established measures of QoL. Regarding the test-retest reliability of FM-QoLS items, the gamma values ranged from 0.923 to 0.995. The FM-QoLS is a 14-item QOL scale specific to patients with fibromyalgia. The scale has high validity and reliability, with no floor and ceiling effects. The FM-QoLS could help physicians address the multifaceted QoL challenges in fibromyalgia patients. Future research could refine the scale by exploring its use in different populations.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 6","pages":"142"},"PeriodicalIF":3.2000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084231/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-025-05895-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The study aimed to develop a quality of life (QoL) scale specific to patients with fibromyalgia. The scale development involved four steps: (1) Issue collection, (2) Face validity and selection of the most relevant items, (3) Formation of the preliminary scale and pilot testing, and (4) Psychometric evaluation. For psychometric evaluation, the scale was administered to a sample of fibromyalgia patients. Suitability for exploratory factor analysis (EFA) was assessed using the Kaiser-Meyer-Olkin (KMO) test and Bartlett's Test of Sphericity. Reliability was assessed with Cronbach's alpha, Guttman split-half test, and test-retest correlations. Construct validity was determined via EFA using Principal Axis Factoring. The correlation of the developed scale with established measures of QoL, fibromyalgia impact, fatigue, sleep, and mood was tested to assess convergent validity. Floor and ceiling effects were also examined. The initial item list included 25 issues related to QoL in fibromyalgia. Following the assessments and rating of the initial issue list through cognitive interviews, 10 issues were removed. The remaining questions were administered to 60 patients with fibromyalgia. The final version of the Fibromyalgia Quality of Life Scale (FM-QoLS) contained 14 items and two domains: symptomatology-functionality and psychosocial. Moderate-strong correlations between most items indicated that the scale has a homogeneous structure and measures the same construct. The FM-QoLS showed moderate-strong correlations with pain, anxiety, depression, sleep, fatigue, and established measures of QoL. Regarding the test-retest reliability of FM-QoLS items, the gamma values ranged from 0.923 to 0.995. The FM-QoLS is a 14-item QOL scale specific to patients with fibromyalgia. The scale has high validity and reliability, with no floor and ceiling effects. The FM-QoLS could help physicians address the multifaceted QoL challenges in fibromyalgia patients. Future research could refine the scale by exploring its use in different populations.

查看原文本刊更多论文

纤维肌痛生活质量量表（FM-QoLS）的发展。

该研究旨在为纤维肌痛患者开发一种特定的生活质量（QoL）量表。量表的开发包括四个步骤：(1)问题收集，(2)面孔效度和选择最相关的项目，(3)初步量表的形成和中试，(4)心理测量评估。为了进行心理测量评估，该量表被用于纤维肌痛患者样本。采用Kaiser-Meyer-Olkin （KMO）检验和Bartlett's球形度检验评估探索性因素分析（EFA）的适用性。信度评估采用Cronbach's alpha、Guttman劈开半检验和重测相关性。构念效度采用主轴因子分析法测定。开发的量表与已建立的生活质量、纤维肌痛影响、疲劳、睡眠和情绪的相关性进行了测试，以评估收敛效度。还研究了地板和天花板效应。最初的项目列表包括与纤维肌痛患者生活质量相关的25个问题。通过认知访谈对初始问题列表进行评估和评级后，删除了10个问题。剩下的问题是对60名纤维肌痛患者进行的。纤维肌痛生活质量量表（FM-QoLS）的最终版本包含14个项目和两个领域：症状-功能和社会心理。大多数条目之间的中强相关性表明量表具有同质结构，测量的是相同的结构。FM-QoLS与疼痛、焦虑、抑郁、睡眠、疲劳和已建立的生活质量指标显示出中强相关性。FM-QoLS项目的重测信度gamma值在0.923 ~ 0.995之间。FM-QoLS是针对纤维肌痛患者的14项生活质量量表。量表具有较高的效度和信度，不存在下限效应和上限效应。FM-QoLS可以帮助医生解决纤维肌痛患者多方面的生活质量挑战。未来的研究可以通过探索它在不同人群中的应用来完善这个量表。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology International 医学-风湿病学

CiteScore

7.30

自引率

5.00%

发文量

191

审稿时长

16. months

期刊介绍： RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology. RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.